Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.128
Neutral
RSI(14)
50.740
Neutral
STOCH(KDJ)(9,3,3)
62.171
Neutral
ATR(14)
0.171
Low Volatility
CCI(14)
72.276
Neutral
Williams %R
25.373
Buy
TRIX(12,20)
-0.326
Sell
StochRSI(14)
59.835
Buy
Biote Corp
BTMD3.450USD
-0.010-0.29%
Close 09/08, 16:00（ET）Quotes delayed by 15 min
109.34MMarket Cap
3.49P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-08Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
5.403
Target Price
+56.17%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.54% year-on-year.
Undervalued
The company’s latest PE is 3.61, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.49M shares, decreasing 13.59% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.42M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.51.
Financial Health
Currency: USD Updated：2025-09-08The company's current financial score is 7.73, which is higher than the Industrial & Commercial Services industry's average of 7.17. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 48.99M, representing a year-over-year increase of 4.67%, while its net profit experienced a year-over-year increase of 762.71%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
6.85
Operational Efficiency
7.52
Growth Potential
7.18
Shareholder Returns
7.10
Company Valuation
Currency: USD Updated：2025-09-08The company’s current valuation score is 1.20, which is lower than the Industrial & Commercial Services industry's average of 2.63. Its current P/E ratio is 3.51, which is 420.46% below the recent high of 18.28 and -23.81% above the recent low of 4.35.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 66/207
No Data
Earnings Forecast
Currency: USD Updated：2025-09-08The company’s current earnings forecast score is 8.33, which is higher than the Industrial & Commercial Services industry's average of 7.74. The average price target for Biote Corp is 5.46, with a high of 8.00 and a low of 3.50.
Score
Support & Resistance
No Data
Analyst Rating
Based on
6
analysts
Buy
Current Rating
5.403
Target Price
+56.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
17
Total
10
Median
11
Average
Company name
Ratings
Analysts
Biote Corp
BTMD
6
Moody's Corp
MCO
25
S&P Global Inc
SPGI
25
Equifax Inc
EFX
24
Factset Research Systems Inc
FDS
21
TransUnion
TRU
20
1
2
3
4
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-08The company’s current price momentum score is 6.92, which is lower than the Industrial & Commercial Services industry's average of 7.82. Sideways: Currently, the stock price is trading between the resistance level at 4.35 and the support level at 2.56, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.444
Buy
MA10
3.403
Buy
MA20
3.198
Buy
MA50
3.709
Sell
MA100
3.717
Sell
MA200
4.409
Sell
Institutional Confidence
Currency: USD Updated：2025-09-08The company’s current institutional recognition score is 7.00, which is lower than the Industrial & Commercial Services industry's average of 7.85. The latest institutional shareholding proportion is 77.07%, representing a quarter-over-quarter decrease of 17.18%. The largest institutional shareholder is The Vanguard, holding a total of 1.42M shares, representing 4.28% of shares outstanding, with 2.19% decrease in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Roystone Capital Management LP
325 Capital LLC
Heyer (Andrew R)
Bandera Partners LLC
BlackRock Institutional Trust Company, N.A.
Heyer (Steven J)
Acadian Asset Management LLC
Dimensional Fund Advisors, L.P.
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated：2025-09-08The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Industrial & Commercial Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.17, which is lower than the Industrial & Commercial Services industry's average of 4.24. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.19
VaR
--
240-Day Maximum Drawdown
+59.31%
240-Day Volatility
+71.40%
Return
Best Daily Return
60 days
+6.62%
120 days
+11.98%
5 years
--
Worst Daily Return
60 days
-24.35%
120 days
-24.35%
5 years
--
Sharpe Ratio
60 days
-0.68
120 days
+0.13
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+59.31%
3 years
+66.27%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.72
3 years
-0.11
5 years
--
Skewness
240 days
-0.29
3 years
-0.32
5 years
--
Volatility
Realised Volatility
240 days
+71.40%
5 years
--
Standardised True Range
240 days
+7.83%
5 years
--
Downside Risk-Adjusted Return
120 days
+15.73%
240 days
+15.73%
Maximum Daily Upside Volatility
60 days
+57.64%
Maximum Daily Downside Volatility
60 days
+57.86%
Liquidity
Average Turnover Rate
60 days
+0.49%
120 days
+0.60%
5 years
--
Turnover Deviation
20 days
+50.95%
60 days
+1.81%
120 days
+22.71%
Peer Comparison
Currency: USD Updated：2025-09-08Biote Corp
BTMD
6.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Brady Corp
BRC
7.97 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AECOM
ACM
7.96 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
McGrath RentCorp
MGRC
7.87 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Construction Partners Inc
ROAD
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Brinks Co
BCO
7.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
